Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders.
about
Substance abuse and schizophrenia: pharmacotherapeutic interventionCannabis and schizophrenia: towards a cannabinoid hypothesis of schizophreniaA double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patientsThe World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.Self-reported cannabis use is inconsistent with the results from drug-screening in youth at ultra high-risk for psychosis in ColoradoBAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence.Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia.Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use DisordersPrescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams.A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications.Psychiatric co-morbidity and substance use disorders: treatment in parallel systems or in one integrated system?Antipsychotic treatment of adolescent dual diagnosis patientsClozapine for the treatment of schizophrenia.Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review.The link between schizophrenia and substance use disorder: A unifying hypothesis.Clozapine Treatment and Cannabis Use in Adolescents with Psychotic Disorders - A Retrospective Cohort Chart ReviewOpioid abuse and hospitalization rates in patients with schizophrenia.Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development?The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis.Evaluation of the performance of a point-of-care method for total and differential white blood cell count in clozapine users.Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis
P2860
Q24621711-D08EE8BB-9543-4060-97B1-A7A08EFAB087Q28285577-3D87C2B9-708D-441D-A729-364698709091Q30422068-5683E4AA-D6B9-47C2-BE92-F27A2CAA2FC5Q33870389-D617025B-8680-41B2-95D5-18E3F2573D66Q34051836-41B4DBE9-C7AD-46AE-B513-EC94DC543CA6Q34277168-BCCE3446-FFA4-4E4C-8B15-A77B31C3898AQ34589479-2E7F9C0A-04AC-4B14-B2A1-E71BAE814EEAQ35136787-15F149BA-CF9D-4D59-8DE7-610A84667642Q35529636-10ED8242-11B0-4D77-8171-496B09643993Q36927085-2B4B07FD-1B8A-4316-8E6B-521CCF01FE4EQ37705255-9A08CB53-1FE1-4445-8A84-257BDC05899CQ37998841-9F6F61A2-5982-44BA-AC71-01AB3FFD3A99Q38016975-AC0B9B01-D483-4277-A7A5-C8790852A701Q38024348-0BFE5B02-56FC-488C-AED9-D2402AEDF11AQ38026886-B6E5264E-3EBF-432B-A743-D524ED04A2A8Q38618558-AC85DA66-F020-4293-BE6C-9702AD93FB83Q38729376-9DCC22BE-EDAA-4A7A-952F-A1346649C2AFQ38885071-BF95E2B9-F8A1-45EC-AAB3-4FAA715B987DQ40600955-156233DC-C226-4499-BFD6-E52035D69B47Q45929001-5E6FA527-BD6D-4E2E-AFFE-89FE99A6E53DQ47832927-F85950D0-8E28-40BB-8935-53E3C775AE43Q47952413-92CF3CFF-2969-425B-8F12-BD8CF8C47ACEQ58738328-6B9100A3-4960-4B60-8653-BA4D184F9E90
P2860
Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 June 2006
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clozapine use and relapses of ...... a and substance use disorders.
@en
Clozapine use and relapses of ...... a and substance use disorders.
@nl
type
label
Clozapine use and relapses of ...... a and substance use disorders.
@en
Clozapine use and relapses of ...... a and substance use disorders.
@nl
prefLabel
Clozapine use and relapses of ...... a and substance use disorders.
@en
Clozapine use and relapses of ...... a and substance use disorders.
@nl
P2093
P2860
P921
P356
P1476
Clozapine use and relapses of ...... a and substance use disorders.
@en
P2093
Alan I Green
Gregory J McHugo
Mary F Brunette
P2860
P304
P356
10.1093/SCHBUL/SBL003
P407
P577
2006-06-16T00:00:00Z